Skip to main content
4-AntibodyPress Release

4-Antibody announces long-term collaboration with Boehringer Ingelheim with a maximum value of EUR 177.5m (CHF 266m) for 4-Antibody

By 16 March 2010January 6th, 2023No Comments
Press Release.


Basel, Switzerland: 4-Antibody AG today announced a major long-term collaboration with Boehringer Ingelheim to discover and to develop fully human therapeutic antibodies for a number of targets in various disease indications.

4-Antibody will use its proprietary and unencumbered Hu-PAC™ and Retrocyte Display™ technologies for the discovery and development of fully human antibodies against novel targets nominated by Boehringer Ingelheim. 4-Antibody AG will receive payments of up to EUR 177.5 million (CHF 266 million) including upfront and milestone payments from Boehringer Ingelheim upon achievement of certain clinical development milestones.


About 4-Antibody AG

4-Antibody AG is a privately held Swiss Biotech company active in the area of therapeutic antibody drug development. 4-Antibody AG has developed a portfolio of powerful, proprietary antibody discovery and engineering platforms, including the Hu-PAC® and the Retrocyte Display® technologies. 4-Antibody AG owns four patent families related to therapeutic antibody discovery platforms and products, including more than a dozen of granted patents worldwide. The company has 40 employees working at its headquarter in Basel, Switzerland, and its subsidiary in Jena, Germany.